Phase 2 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have already completed the related SPN-817 double-blind study.
- People who have been taking a steady dose of at least one but no more than four anti-seizure medications throughout the previous study.
Who may not be able to join:
- People who experience non-epileptic events that could be mistaken for epileptic seizures by the person themselves or by study staff.
- People who, based on a standardised suicide risk assessment (called the Columbia-Suicide Severity Rating Scale), showed certain levels of active suicidal thoughts or intentions during the previous study or at the first visit — or people who have made more than one suicide attempt in their lifetime.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.
Phone: 240-403-5838
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of treatment-emergent adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.